TORONTO, Feb. 28 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it will present new findings demonstrating the clinical utility of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, at the 12th Annual Critical Care for Endotoxemia congress. The conference takes place in Fukuoka, Japan from February 28th-29th, 2008 and focuses on the role of endotoxemia in sepsis in critically ill patients. The Company and a number of leading medical centres in Japan including the Tokyo Medical Clinic, Osaka City General Hospital and Iwate Medical University will each present findings using data collected with Spectral’s EAA(TM) product that highlight the clinical utility of the diagnostic.
